{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:27Z","timestamp":1792788027589,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Henan Provincial Medical Science and Technology Key Research Project","award":["RKX202401006"],"award-info":[{"award-number":["RKX202401006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-025-13322-3","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:57:56Z","timestamp":1756277876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness analysis of first-line gifitinib plus pemetrexed-platinum-based chemotherapy versus gifitinib monotherapy in EGFR-mutated NSCLC patients with brain metastases"],"prefix":"10.1186","volume":"25","author":[{"given":"Ziying","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maolin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuzhou","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"issue":"1","key":"13322_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33365-y","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Abdo R, Iosef C, Kaneko T, Cecchini M, Han VK, Li SS. The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis. Nat Commun. 2022;13(1): 5983. https:\/\/doi.org\/10.1038\/s41467-022-33365-y.","journal-title":"Nat Commun"},{"issue":"1","key":"13322_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78\u201384. https:\/\/doi.org\/10.1016\/j.lungcan.2014.07.020.","journal-title":"Lung Cancer"},{"key":"13322_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00208","volume":"8","author":"WJ Kelly","year":"2018","unstructured":"Kelly WJ, Shah NJ, Subramaniam DS. Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer. Front Oncol. 2018;8: 208. https:\/\/doi.org\/10.3389\/fonc.2018.00208.","journal-title":"Front Oncol"},{"issue":"2","key":"13322_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11060-017-2590-x","volume":"135","author":"M Ge","year":"2017","unstructured":"Ge M, Zhuang Y, Zhou X, Huang R, Liang X, Zhan Q. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases. J Neurooncol. 2017;135(2):413\u20138. https:\/\/doi.org\/10.1007\/s11060-017-2590-x.","journal-title":"J Neurooncol"},{"issue":"1","key":"13322_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","volume":"88","author":"D Rangachari","year":"2015","unstructured":"Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, Costa DB. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015;88(1):108\u201311. Epub 2015 Feb 4. PMID: 25682925.","journal-title":"Lung Cancer"},{"issue":"2","key":"13322_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/JTO.0000000000000069","volume":"9","author":"DY Shin","year":"2014","unstructured":"Shin DY, Na II, Kim CH, Park S, Baek H, Yang SH. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol. 2014;9(2):195\u20139. https:\/\/doi.org\/10.1097\/JTO.0000000000000069.","journal-title":"J Thorac Oncol"},{"key":"13322_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.lungcan.2016.04.004","volume":"96","author":"F Hsu","year":"2016","unstructured":"Hsu F, De Caluwe A, Anderson D, Nichol A, Toriumi T, Ho C. EGFR mutation status on brain metastases from non-small cell lung cancer. Lung Cancer. 2016;96:101\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2016.04.004.","journal-title":"Lung Cancer"},{"issue":"25","key":"13322_CR8","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380\u20138. https:\/\/doi.org\/10.1056\/NEJMoa0909530.","journal-title":"N Engl J Med"},{"issue":"8","key":"13322_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(11)70184-X.","journal-title":"Lancet Oncol"},{"issue":"9","key":"13322_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2213-2600(17)30262-X","volume":"5","author":"JJ Yang","year":"2017","unstructured":"Yang JJ, Zhou C, Huang Y, Feng J, Lu S, Song Y, Huang C, Wu G, Zhang L, Cheng Y, Hu C, Chen G, Zhang L, Liu X, Yan HH, Tan FL, Zhong W, Wu YL. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Lancet Respir Med. 2017;5(9):707\u201316. https:\/\/doi.org\/10.1016\/S2213-2600(17)30262-X.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"13322_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55050","volume":"6","author":"X Hou","year":"2023","unstructured":"Hou X, Li M, Wu G, Feng W, Su J, Jiang H, Jiang G, Chen J, Zhang B, You Z, Liu Q, Chen L. Gefitinib plus chemotherapy vs gefitinib alone in untreated EGFR-mutant non-small cell lung cancer in patients with brain metastases: the GAP BRAIN open-label, randomized, multicenter, phase 3 study. JAMA Netw Open. 2023;6(2): e2255050. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.55050.","journal-title":"JAMA Netw Open"},{"key":"13322_CR12","unstructured":"Chinese Pharmaceutical Association. Chinese Guidelines for Pharmacoeconomic Evaluations. (2020) Available at: https:\/\/www.zixin.com.cn\/doc\/4150052.pdf."},{"key":"13322_CR13","unstructured":"National Bureau Of Statistics Of China. China statistical yearbook 2022. Accessed November 14. 2022. http:\/\/www.stats.gov.cn"},{"key":"13322_CR14","first-page":"201","volume-title":"Guidelines of Chinese society of clinical oncology (CSCO) for non-small cell lung cancer [M] 2021 edition","author":"Guidelines Working Committee of Chinese society of Clinical Oncology","year":"2021","unstructured":"Guidelines Working Committee of Chinese society of Clinical Oncology. Guidelines of Chinese society of clinical oncology (CSCO) for non-small cell lung cancer [M] 2021 edition. Beijing: People\u2019s Medical Publishing House; 2021. p. 201."},{"key":"13322_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. https:\/\/doi.org\/10.1186\/1471-2288-12-9. PMID: 22297116; PMCID: PMC3313891.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"13322_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2165\/00019053-200725010-00002","volume":"25","author":"RL Fleurence","year":"2007","unstructured":"Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics. 2007;25(1):3\u20136. https:\/\/doi.org\/10.2165\/00019053-200725010-00002.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"13322_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1524-4733.2008.00415.x","volume":"12","author":"JJ Carlson","year":"2009","unstructured":"Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health. 2009;12(1):20\u20137. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00415.x.","journal-title":"Value Health"},{"issue":"2","key":"13322_CR18","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1111\/ajco.13291","volume":"17","author":"W Li","year":"2021","unstructured":"Li W, Bai R, Qian L, Chen N, Zhao Y, Han F, Bai L, Li J, Yu Y, Cui J. Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases. Asia Pac J Clin Oncol. 2021;17(2):e40-7. https:\/\/doi.org\/10.1111\/ajco.13291.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"13322_CR19","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1111\/ajco.12477","volume":"13","author":"B Nafees","year":"2017","unstructured":"Nafees B, Lloyd AJ, Dewilde S, Rajan N, Lorenzo M. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13(5):e195-203. https:\/\/doi.org\/10.1111\/ajco.12477.","journal-title":"Asia Pac J Clin Oncol"},{"key":"13322_CR20","unstructured":"China\u2019s health industry data platform. Bid winning information of drugs. Accessed September 14. 2021. https:\/\/www.yaozh.com\/"},{"key":"13322_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.788569","volume":"12","author":"Q Liu","year":"2021","unstructured":"Liu Q, Zhou Z, Luo X, Yi L, Peng L, Wan X, Tan C, Zeng X. First-line ICI monotherapies for advanced non-small-cell lung cancer patients with PD-L1 of at least 50%: a cost-effectiveness analysis. Front Pharmacol. 2021;12: 788569.","journal-title":"Front Pharmacol"},{"key":"13322_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.832215","volume":"13","author":"X Luo","year":"2022","unstructured":"Luo X, Liu Q, Zhou Z, Yi L, Peng L, Wan X, Zeng X, Tan C, Li S. Cost-effectiveness of bevacizumab biosimilar LY01008 combined with chemotherapy as first-line treatment for Chinese patients with advanced or recurrent nonsquamous non-small cell lung cancer. Front Pharmacol. 2022;13: 832215. https:\/\/doi.org\/10.3389\/fphar.2022.832215.","journal-title":"Front Pharmacol"},{"key":"13322_CR23","doi-asserted-by":"publisher","first-page":"935581","DOI":"10.3389\/fphar.2022.935581","volume":"13","author":"X Luo","year":"2022","unstructured":"Luo X, Zhou Z, Zeng X, Liu Q. The cost-effectiveness of Tislelizumab plus chemotherapy for locally advanced or metastatic nonsquamous non-small cell lung cancer. Front Pharmacol. 2022;13:935581. https:\/\/doi.org\/10.3389\/fphar.2022.935581. PMID: 35935852; PMCID: PMC9354466.","journal-title":"Front Pharmacol"},{"issue":"5","key":"13322_CR24","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989X12458348","volume":"32","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD, ISPOR-SMDM Modeling Good Research Practices Task Force. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Making. 2012;32(5):722\u201332. https:\/\/doi.org\/10.1177\/0272989X12458348.","journal-title":"Med Decis Making"},{"key":"13322_CR25","unstructured":"National Healthcare Security Administration. Dynamic deepening of medical insurance reform of drugs and high value medical consumables centralized procurement progress of the state Council policy routine briefing nhsa.gov.cn (Accessed 23 sep 2022)."},{"key":"13322_CR26","unstructured":"International Agency for Research on Cancer. Cancer Fact Sheets [Internet]. 2020 Dec 18 [cited 2023 May 5]. Available from: https:\/\/gco.iarc.fr\/today\/en\/dataviz\/tables?mode=population."},{"key":"13322_CR27","doi-asserted-by":"publisher","unstructured":"Pan F. Comprehensive management is needed to reduce the incidence and mortality of lung Cancer - An interview with professor Li danqing, director of thoracic surgery, Peking union medical college hospital. Chin J Med Gui. 2021;18(20):1-3. https:\/\/doi.org\/10.20047\/j.issn1673-7210.2021.20.001.","DOI":"10.20047\/j.issn1673-7210.2021.20.001"},{"issue":"1","key":"13322_CR28","first-page":"1","volume":"20","author":"YK Shi","year":"2017","unstructured":"Shi YK, Sun Y, Yu JM, Ding CM, Ma ZY, Wang ZP, Wang D, Wang Z, Wang MZ, Wang Y, Lu Y, Ai B, Feng JF, Liu YP, Liu XQ, Liu JW, Wu G, Qu BL, Li XJ, Li EX, Li W, Song Y, Chen GY, Chen ZT, Chen J, Yu P, Wu N, Wu ML, Xiao WH, Xiao JP, Zhang L, Zhang Y, Zhang YP, Zhang SC, Song X, Luo RC, Zhou CC, Zhou ZM, Zhao Q, Hu CP, Hu Y, Nie LG, Guo QS, Chang JH, Huang C, Han BH, Li G, Huang YW, Shi YW. Chinese expert consensus on the diagnosis and treatment of brain metastases in lung cancer (2017 Version). Chin J Lung Cancer. 2017;20(1):1\u201312.","journal-title":"Chin J Lung Cancer"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13322-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-13322-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13322-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:50:10Z","timestamp":1757443810000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-13322-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13322"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-13322-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5385943\/v1","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, because our economic evaluation is based on a mathematical model analysis, and does not contain any studies with human participants or animals performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"1136"}}